Citations

Mayo Clinic

Showing 10 of 108585 citations.

AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Cancer Prevention Research | September 21, 2023 | Volume: 16 | Issue: 11 | Pages: 591-594

10.1158/1940-6207.capr-23-0379 | PMID 37732897 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Arteaga, Carlos L. , Cleveland, John L. , Foti, Margaret , Mesa, Ruben A. , Weiner, Louis M. , Willman, Cheryl L. , Tuveson, David A. , Mesa, Ruben , Willman, Cheryl , Cleveland, John L

Molecular Cancer Research | September 21, 2023 | Volume: 21 | Issue: 11 | Pages: 1139-1141

10.1158/1541-7786.mcr-23-0750 | PMID 37732893 Get It

Abstract Basic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing resources, developing national demonstration projects, and driving innovation that impacts cancer science, cancer care delivery, and science and health policy.
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer
Ali, Lestat R. , Lenehan, Patrick J. , Cardot‐Ruffino, Victoire , Costa, Andressa Dias , Bauer, Todd W. , Nowak, Jonathan A. , Wolpin, Brian M. , Abrams, Thomas A. , Patel, Anuj , Clancy, Thomas E. , Wang, Jiping , Mancias, Joseph D. , Stucky, Chee‐Chee , Bekaii‐Saab, Tanios , Merchant, Nipun B. , Slingluff, Craig L. , Rahma, Osama E. , Dougan, Stephanie K. , Dias Costa, Andressa , Katz, Matthew H G , Bauer, Todd W , Nowak, Jonathan A , Wolpin, Brian M , Abrams, Thomas A , Patel, Anuj , Clancy, Thomas E , Wang, Jiping , Mancias, Joseph D , Reilley, Matthew J , Stucky, Chee-Chee H , Bekaii-Saab, Tanios S , Elias, Rawad , Merchant, Nipun , Slingluff, Craig L , Rahma, Osama E , Dougan, Stephanie K , Lenehan, Patrick J , Katz, Matthew H. G. , Reilley, Matthew J. , Elias, Rawad

Clinical Cancer Research | September 21, 2023 | Volume: 30 | Issue: 3 | Pages: 542-553

10.1158/1078-0432.ccr-23-1444 | PMID 37733830 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors. Experimental Design: We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor. Results: PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to PD-1 blockade. However, these reactivated T cells have a robust signature of NF-κB signaling not seen in cases of PD-1 antibody response. Among paired samples between blood and tumor, several of the newly cycling clonotypes matched activated T-cell clonotypes observed in the tumor. Conclusions: Cytotoxic T cells in the blood of patients with PDAC remain sensitive to reinvigoration by PD-1 blockade, and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti–PD-1 reinvigoration and marks these T cells as non-productive contributors to antitumor immunity. See related commentary by Lander and DeNardo, p. 474
Mycobacterium abscessus subspecies identification using the Deeplex Myc-TB targeted NGS assay
Buckwalter, Seanne P., Olson, Sara L., Epperson, L. Elaine , Hasan, Nabeeh A. , Khare, Reeti , Strong, Michael , Wengenack, Nancy L. , Wengenack, Nancy L , Fida, Madiha

Journal of Clinical Microbiology | September 21, 2023 | Volume: 61 | Issue: 10 | Pages: No page available

10.1128/jcm.00489-23 | PMID 37732763 Get It

Arterial Hyperoxemia During Cardiopulmonary Bypass Was Not Associated With Worse Postoperative Pulmonary Function: A Retrospective Cohort Study
Kelava, Marta , Milam, Adam J. , Mi, Junhui, Alfirevic, Andrej , Grady, Patrick, Unai, Shinya , Elgharably, Haytham , McCurry, Kenneth R. , Koprivanac, Marijan , Duncan, Andra E. , Milam, Adam J , Mi, Junhui, Grady, Patrick

Anesthesia & Analgesia | September 21, 2023 | Volume: 138 | Issue: 5 | Pages: 1003-1010

10.1213/ane.0000000000006627 | PMID 37733624 Get It

BACKGROUND: Arterial hyperoxemia may cause end-organ damage secondary to the increased formation of free oxygen radicals. The clinical evidence on postoperative lung toxicity from arterial hyperoxemia during cardiopulmonary bypass (CPB) is scarce, and the effect of arterial partial pressure of oxygen (Pa o 2 ) during cardiac surgery on lung injury has been underinvestigated. Thus, we aimed to examine the relationship between Pa o 2 during CPB and postoperative lung injury. Secondarily, we examined the relationship between Pa o 2 and global (lactate), and regional tissue malperfusion (acute kidney injury). We further explored the association with regional tissue malperfusion by examining markers of cardiac (troponin) and liver injury (bilirubin). METHODS: This was a retrospective cohort study including patients who underwent elective cardiac surgeries (coronary artery bypass, valve, aortic, or combined) requiring CPB between April 2015 and December 2021 at a large quaternary medical center. The primary outcome was postoperative lung function defined as the ratio of Pa o 2 to fractional inspired oxygen concentration (F io 2 ); P/F ratio 6 hours following surgery or before extubation. The association between CPB in-line sample monitor Pa o 2 and primary, secondary, and exploratory outcomes was evaluated using linear or logistic regression models adjusting for available baseline confounders. RESULTS: A total of 9141 patients met inclusion and exclusion criteria, and 8429 (92.2%) patients had complete baseline variables available and were included in the analysis. The mean age of the sample was 64 (SD = 13), and 68% were men (n = 6208). The time-weighted average (TWA) of in-line sample monitor Pa o 2 during CPB was weakly positively associated with the postoperative P/F ratio. With a 100-unit increase in Pa o 2 , the estimated increase in postoperative P/F ratio was 4.61 (95% CI, 0.71–8.50; P = .02). Our secondary analysis showed no significant association between Pa o 2 with peak lactate 6 hours post CPB (geometric mean ratio [GMR], 1.01; 98.3% CI, 0.98–1.03; P = .55), average lactate 6 hours post CPB (GMR, 1.00; 98.3% CI, 0.97–1.03; P = .93), or acute kidney injury by Kidney Disease Improving Global Outcomes (KDIGO) criteria (odds ratio, 0.91; 98.3% CI, 0.75–1.10; P = .23). CONCLUSIONS: Our investigation found no clinically significant association between Pa o 2 during CPB and postoperative lung function. Similarly, there was no association between Pa o 2 during CPB and lactate levels, postoperative renal function, or other exploratory outcomes.
Meeting Report: 11th and 12th Annual Meetings of the Society of Anesthesia and Sleep Medicine: Taking Sleep Health Into the Next Decade
Pappu, Ameya , Ramachandran, Satya Krishna , Auckley, Dennis , Won, Christine , Gali, Bhargavi , Hargett, Mary J. , Nafiu, Olubukola O. , Dominguez, Jennifer E. , Singh, Mandeep

Anesthesia & Analgesia | September 21, 2023 | Volume: 137 | Issue: 6 | Pages: e45-e48

10.1213/ane.0000000000006632 | PMID 40009003 Get It

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
Saunders, Edward J. , Sheng, Xin , Wan, Peggy , Pooler, Loreall , Xia, Lucy , Chanock, Stephen, Berndt, Sonja I., Patel, Alpa V. , Albanes, Demetrius, Weinstein, Stephanie J. , Gnanapragasam, Vincent J. , Huff, Chad D. , Pomerantz, Mark M., Schmidt, Julie A. , Travis, Ruth C. , Mucci, Lorelei A. , Catàlona, William J. , Marosy, Beth, Hetrick, Kurt N. , Doheny, Kimberly F. , MacInnis, Robert J. , Eeles, Rosalind A. , Kote‐Jarai, Zsofia , Haiman, Christopher A. , Eeles, Rosalind A , Travis, Ruth C , Maclnnis, Robert , Darst, Burcu F. , Dadaev, Tokhir , Berndt, Sonja I. , Wang, Ying , Couch, Fergus J. , Wolk, Alicja , Giles, Graham G. , Nguyen‐Dumont, Tú , Milne, Roger L. , Key, Tim , Stopsack, Konrad H. , Southey, Melissa C. , Wiklund, Fredrik E. , Conti, David V.

JAMA Oncology | September 21, 2023 | Volume: 9 | Issue: 11 | Pages: 1514

10.1001/jamaoncol.2023.3482 | PMID 37733366 Get It

Importance Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective To identify genes associated with aggressive PCa. Design, Setting, and Participants A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. Exposure Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. Main Outcomes and Measures The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. Results A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM ( P ≤ 1.9 × 10 −6 ), followed by NBN ( P = 1.7 × 10 −4 ). This study found nominal evidence ( P < .05) of association with rare deleterious variants in MSH2 , XRCC2 , and MRE11A . Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53 , RAD51D , BARD1 , GEN1 , and SLX4 . Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. Conclusions and Relevance The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, Mary E. , Lieu, Hsiao D., Goodman, Zachary , Alkhouri, Naim , Abdelmalek, Manal F. , Wong, Vincent Wai‐Sun , Younes, Ziad , Sheikh, Aasim , Brannan, Donald, Freilich, B., Membreno, Fernando E., Sinclair, Marie , Melchor‐Khan, Liza, Ling, Lei , Abdelmalek, Manal , Wong, Vincent Wai-Sun , Rinella, Mary , Kowdley, Kris V. , Lawitz, Eric , Ratziu, Vlad , Brannan, Donald, Sanyal, Arun J. , Harrison, Stephen A.

Hepatology | September 21, 2023 | Volume: 79 | Issue: 3 | Pages: 674-689

10.1097/hep.0000000000000607 | PMID 37732990 Get It

Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Lemoinne, Sara , Soret, Pierre‐Antoine , Gulamhusein, Aliya , Lytvyak, Ellina , Olivas, Ignasi , Eaton, John E. , Sebode, Marcial , Lohse, Ansgar W. , Nevens, Frederik , Cazzagon, Nora , Zago, Alessandra , Russo, Francesco Paolo , Floreani, Annarosa , Abbas, Nadir , Thorburn, Douglas , Delamarre, Adèle , Sobenko, Natalia , Villamil, Alejandra , Patwardhan, Vilas , Rigamonti, Cristina , Meer, Adriaan van der , Veer, Rozanne de, Zigmond, Ehud , Yehezkel, Eyal , Bruns, Tony , Große, Karsten , Wetten, Aaron , Jones, David , Dumortier, Jérôme , Pageaux, Georges‐Philippe , Lédinghen, Victor de , Chazouillères, Olivier , Groups, the Global & ERN Rare-Liver PBC Study, Osman, Karim T. , Bruns, Tony , Patwardhan, Vilas R , Lytvyak, Ellina , Corpechot, Christophe , Hansen, Bettina E. , Hirschfield, Gideon M. , Montaño‐Loza, Aldo J. , Parés, Albert , Schramm, Christoph , Dalekos, George Ν. , Gatselis, Nikolaos , Abbas, Nadir , Trivedi, Palak Jitendrakumar , Saffioti, Francesca , Barkai, László , Roccarina, Davide , Calvaruso, Vincenza , Fichera, Anna, Villamil, Alejandra , Medina‐Morales, Esli , Bonder, Alan , Carbone, Marco , Invernizzi, Pietro , Cristoferi, Laura , Kremer, Andreas E. , Deibel, Ansgar , Dyson, Jessica Katharine , Carrat, Fabrice , Groups, the Global & ERN Rare-Liver PBC Study, Russo, Francesco Paolo

Hepatology | September 21, 2023 | Volume: 79 | Issue: 1 | Pages: 39-48

10.1097/hep.0000000000000529 | PMID 37399238 Get It

Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. Approach and Results: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7–21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7–59.9, p < 0.001) when these 2 conditions were met. Conclusions: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.